Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03168100
Title 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Arkansas

multiple myeloma


Bortezomib + Dexamethasone + Lenalidomide

Dexamethasone + Elotuzumab + Lenalidomide

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.